Show simple item record

dc.contributor.authorPeterson, Roseann E
dc.date.accessioned2023-02-13T19:37:31Z
dc.date.available2023-02-13T19:37:31Z
dc.date.issued2021-04-01
dc.identifier.citationPeterson RE. The Genetics of Major Depression: Perspectives on the State of Research and Opportunities for Precision Medicine. Psychiatr Ann. 2021 Apr;51(4):165-169. doi: 10.3928/00485713-20210315-01. Epub 2021 Apr 1. PMID: 35291372; PMCID: PMC8920347.en_US
dc.identifier.issn0048-5713
dc.identifier.doi10.3928/00485713-20210315-01
dc.identifier.pmid35291372
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8349
dc.description.abstractMajor depression (MD) is a leading cause of disability worldwide; it arises from the action and interaction between genetic and environmental factors, and is often comorbid with other psychiatric and medical conditions. To date, upwards of 100 genetic loci have been associated with MD, giving clues to biological underpinnings. Although recent progress has yielded modest insight into the genetic architecture of MD, most studies have been in populations with European ancestry, seriously limiting precision medicine efforts. Broadening diversity of study populations will empower genomic research by expanding discovery and enhancing our understanding of the role of genomic variation in disease etiology. To fully realize the potential of pharmacogenetics and precision medicine, we will need to address the major gaps in our knowledge of the genetic and environmental risk architecture of MD across ancestries, including sex differences, to improve etiologic understanding, diagnosis, prevention, and treatment for all.
dc.language.isoenen_US
dc.relation.urlhttps://journals.healio.com/doi/10.3928/00485713-20210315-01en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleThe Genetics of Major Depression: Perspectives on the State of Research and Opportunities for Precision Medicine.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitlePsychiatric annalsen_US
dc.source.volume51
dc.source.issue4
dc.source.beginpage165
dc.source.endpage169
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.description.versionAMen_US
refterms.dateFOA2023-02-13T19:37:32Z
html.description.abstractMajor depression (MD) is a leading cause of disability worldwide; it arises from the action and interaction between genetic and environmental factors, and is often comorbid with other psychiatric and medical conditions. To date, upwards of 100 genetic loci have been associated with MD, giving clues to biological underpinnings. Although recent progress has yielded modest insight into the genetic architecture of MD, most studies have been in populations with European ancestry, seriously limiting precision medicine efforts. Broadening diversity of study populations will empower genomic research by expanding discovery and enhancing our understanding of the role of genomic variation in disease etiology. To fully realize the potential of pharmacogenetics and precision medicine, we will need to address the major gaps in our knowledge of the genetic and environmental risk architecture of MD across ancestries, including sex differences, to improve etiologic understanding, diagnosis, prevention, and treatment for all.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPsychiatry and Behavioral Sciencesen_US
dc.description.departmentInstitute for Genomics in Healthen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalPsychiatric annals


Files in this item

Thumbnail
Name:
nihms-1784774.pdf
Size:
53.42Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International